Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Semma Therapeutics Inc.

www.semma-tx.com

Latest From Semma Therapeutics Inc.

Deal Watch: BMS To Tap Early-Stage Breakthroughs In Partnership With BioMotiv

Bristol-Myers Squibb will partner with the biotech accelerator to fund and launch biotechs, with the pharma getting an option to buy. Novartis signs another agreement with IFM months after buying its IFM Tre affiliate.

Deals Business Strategies

Vertex Buys Semma, Gaining Cell Therapy-Based Type 1 Diabetes Treatments

Semma's innovative technology involves growing insulin-producing beta cells from stem cells and transplanting them into the liver, but it hasn't been tested in humans yet.

Deals Metabolic Disorders

Encapsulated Living Cells For Diabetes: The Final Push?

Lilly has linked up with US biotech Sigilon Therapeutics to develop encapsulated cell therapies for diabetes, a second "living therapeutics" approach to the condition to attract funding in the past six months.

 

Deals Metabolic Disorders

Finance Watch: VC Interest Lags At Early Stage – 'Hogwash' Or Evidence-Based?

Venture Capital Edition: A VC investor at a recent conference said it's "hogwash" that venture capitalists aren't interested in funding early-stage biopharma, but the trend toward large financings – such as the $220m raised to date by Rubius – and 2017 investment data suggest otherwise.

Financing Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Medical Devices
  • Pharmaceuticals
  • Therapeutic Areas
  • Metabolic Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • Semma Therapeutics Inc.
  • Senior Management
  • Bastiano Sanna, PhD, Pres. & CEO
    Mary Kay Fenton, CFO
    David Lebwohl, MD, CMO
  • Contact Info
  • Semma Therapeutics Inc.
    Phone: (857) 529-6430
    100 Technology Sq., Fl. 3
    Cambridge, MA 02139
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register